Although the niraparib package insert and clinical case reports have indicated that it can cause rash, diarrhea, intestinal perforation, peripheral edema, bronchitis, conjunctivitis, gamma-glutamyl transferase increased, albumin decreased, blood alkaline phosphatase increased, depression and cardiac arrest in ovarian cancer cancer patients, the signal strength did not meet the criteria in our analysis. This evidence concerns the gene ALB and ovarian carcinoma.